Targeting 'Achilles' heel' could supercharge breast cancer treatment

August 2, 2017
A new class of anti-cancer agents that target cancer cells' 'Achilles' heel' could help to supercharge breast cancer treatment, improving outcomes for some of the most aggressive types of breast cancer.A research team from the Walter and Eliza Hall Institute in Melbourne, Australia, found that combining anti-cancer compound S63845 with currently used cancer drugs was more effective in killing triple negative breast cancers and HER2-positive breast cancers.L-R: Dr François Vaillant, Dr James Whittle and Dr Delphine Merino Credit: Walter and Eliza Hall Institute

A new class of anti-cancer agents that target cancer cells' 'Achilles' heel' could help to supercharge breast cancer treatment, improving outcomes for some of the most aggressive types of breast cancer.

Combining anti-cancer compound S63845 with currently used cancer drugs was more effective in killing triple negative cancers and HER2-positive breast cancers. This is the first time the S63845 compound, developed by pharmaceutical company Servier, has been shown to be effective for treating , with the promising results suggesting it should be investigated in clinical trials.

The results are particularly important for triple negative breast cancers because, unlike other breast cancers, they have not seen substantial improvements in treatment or patient outcomes in the past 30 years.

The research was led by Dr Delphine Merino, Dr James Whittle, Dr François Vaillant, Professor Jane Visvader and Professor Geoff Lindeman from Melbourne's Walter and Eliza Hall Institute, in collaboration with Servier. The study was published today in Science Translational Medicine.

Professor Lindeman, also a medical oncologist at the Peter Mac and Royal Melbourne Hospital, said MCL-1 inhibitor S63845 was one of a promising new class of drugs that triggers tumour cell death by targeting the cancer's 'Achilles' heel'. "Our hope is that it will be possible to combine MCL-1 inhibitors with conventional therapies to more effectively treat certain types of breast cancer and deliver better outcomes for our patients," Professor Lindeman said.

Around one in three Australian women with breast cancer have a triple negative or HER2-positive breast cancer. Triple negative breast cancers are particularly common in women with a faulty BRCA1 gene.

Dr Merino said S63845 was particularly effective in treating triple negative and HER-2 positive breast cancers, when tested in samples taken from patients' tumours. "Combining S63845 with standard therapies, such as chemotherapy or targeted drugs such as Herceptin, proved highly effective in killing these very aggressive tumour types," Dr Merino said.

Dr Whittle, who is also a medical oncologist at Peter Mac, said S63845 targeted MCL-1, a protein that Institute scientists had previously shown to be important for cancer cell survival. "MCL-1 gives cancer cells a survival advantage, allowing them to resist chemotherapy or other anti-cancer therapies that would otherwise trigger cancer cell death," Dr Whittle said.

"Importantly, the combination of the MCL-1 inhibitor S63845 with standard therapies was far more effective than either treatment alone. These can be incredibly aggressive tumours, so to see a response to the combined in this tumour type is very exciting."

MCL-1 is a critical anti-cancer therapeutic target. It is found at excessive levels in triple negative and HER2-positive breast cancers, and is often associated with poor outcomes for patients.

A new class of anti-cancer agents that target cancer cells' 'Achilles' heel' could help to supercharge breast cancer treatment, improving outcomes for some of the most aggressive types of breast cancer.A research team from the Walter and Eliza Hall Institute in Melbourne, Australia, found that combining anti-cancer compound S63845 with currently used cancer drugs was more effective in killing triple negative breast cancers and HER2-positive breast cancers. L-R: Professor Jane Visvader, Professor Geoff Lindeman, Dr James Whittle, Dr Delphine Merino and Dr François Vaillant Credit: Walter and Eliza Hall Institute

Professor Lindeman said triple negative breast cancers in particular were in urgent need of new treatment options. "Triple negative breast cancers have not seen the same improvement in targeted therapies, or survival, as some other types of breast cancer," he said.

Dr Vaillant said patient-derived tumours provided a valuable way of studying new breast cancer drugs.

"With the support of the Victorian Cancer Biobank, and samples donated by , we have generated a large number of laboratory models that mimic how tumours behave and respond to therapy in the patient, allowing us to test a range of anti- drugs. This approach can help fast-track the development and transfer of promising drugs to the clinic," Dr Vaillant said.

Explore further: New treatment hope for women with BRCA1 breast cancers

More information: D. Merino el al., "Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer," Science Translational Medicine (2017). stm.sciencemag.org/lookup/doi/ … scitranslmed.aam7049

Related Stories

New treatment hope for women with BRCA1 breast cancers

June 7, 2017
Researchers have found a new way to use immunotherapy, a breakthrough mode of cancer treatment which harnesses the patient's immune system, to treat an aggressive form of breast cancer.

Even low-androgen triple-negative breast cancer responds to anti-androgen therapy

February 24, 2015
A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics shows that only about 1 percent of triple-negative breast cancer cells in a tumor must be "androgen-receptor-positive" ...

Promising findings towards targeted breast cancer therapy

November 14, 2016
New research led by Conway Fellow, Professor Joe Duffy and Professor John Crown in St Vincent's University Hospital has reported for the first time on a new treatment that could be used in the majority of patients with triple ...

Discovery of potential treatment for aggressive form of breast cancer

November 2, 2016
A new drug could be used to treat one of the most aggressive forms of breast cancer, a research centre based at University College Dublin and St Vincent's Hospital has discovered.

New agents show promise for treating aggressive breast cancers

July 18, 2011
Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

New anti-cancer compound shows promise for breast cancer

July 8, 2013
Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer.

Recommended for you

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.